1-hydroxy-4-iodooxindole | 131387-94-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-hydroxy-4-iodooxindole
• 英文别名: 1,3-dihydro-1-hydroxy-4-iodo-2H-indol-2-one；1-hydroxy-4-iodo-1,3-dihydro-indol-2-one；1-hydroxy-4-iodo-1,3-dihydroindol-2-one；1-hydroxy-4-iodo-3H-indol-2-one
• CAS: 131387-94-5
• 化学式: C₈H₆INO₂
• 分子量: 275.046
• InChiKey: QPTLYMZPCLYBTQ-UHFFFAOYSA-N

物化性质

• 熔点：
  228-230 °C(Solv: water (7732-18-5); ethanol (64-17-5))
• 沸点：
  396.7±52.0 °C(Predicted)
• 密度：
  2?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-hydroxy-4-iodooxindole 在 哌啶 、 4,4'-二氨基二苯乙烯-2,2'-二磺酸 作用下， 以 二氯甲烷 、 异丙醇 为溶剂， 生成 (Z)-1,3-dihydro-5-fluoro-4-iodo-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2H-indol-2-one
  参考文献：
  名称：

  A new series of potent oxindole inhibitors of CDK2

  摘要：

  A novel series of oxindole-type inhibitors of CDK2 that have heteroatom substituted alkynyl moieties at their C-4 position is described. These novel 4-alkynyl-substituted inhibitors have superior potency relative to their parent compound in free enzyme and in cell based assays. The crystal structure of CDK2 in complex with one of these analogues was determined and gives insight to their increased potency. The biochemical evaluation of a representative derivative is also described.

  DOI：

  10.1016/j.bmcl.2003.12.009
• 作为产物：
  描述：

  (2-iodo-6-nitro-phenyl)-acetic acid 在 钯 氢气 、 silica gel 、 1-hydroxy-4-iodooxindole 作用下， 以 乙醇 为溶剂， 反应 2.0h， 以to obtain the title compound 1-hydroxy-4-iodo-1,3-dihydro-indol-2-one 74e (516 mg, yield 63.4%) as a white solid的产率得到1-hydroxy-4-iodooxindole
  参考文献：
  名称：

  Methods of Inhibiting the Catalytic Activity of a Protein Kinase and of Treating a Protein Kinase Related Disorder

  摘要：

  本发明提供了一种抑制蛋白激酶催化活性的方法，包括将该蛋白激酶与式(I)的化合物或其药学上可接受的盐或含有该化合物的制剂接触。本发明还提供了一种治疗与蛋白激酶相关的疾病的方法，包括向需要治疗的患者施用式(I)的化合物或其药学上可接受的盐或含有该化合物的制剂的治疗有效量。式(I)中的每个取代基与说明书中定义的相同。

  公开号：

  US20130303518A1
• 作为试剂：
  描述：

  (2-iodo-6-nitro-phenyl)-acetic acid 在 钯 氢气 、 silica gel 、 1-hydroxy-4-iodooxindole 作用下， 以 乙醇 为溶剂， 反应 2.0h， 以to obtain the title compound 1-hydroxy-4-iodo-1,3-dihydro-indol-2-one 74e (516 mg, yield 63.4%) as a white solid的产率得到1-hydroxy-4-iodooxindole
  参考文献：
  名称：

  PYRROLO-NITROGENOUS HETEROCYCLIC DERIVATIES,THE PREPARATION AND THE PHARMCETICAL USE THEEOF

  摘要：

  本发明提供了新的吡咯-含氮杂环衍生物，其由式(I)或其盐所代表，其制备方法，含有这种衍生物的制药组合物以及这种衍生物作为治疗剂的用途，特别是作为蛋白激酶抑制剂。在式(I)中，每个取代基的定义如描述中所述。

  公开号：

  US20100075952A1

文献信息

• 4-alkenyl-and 4-alkynyloxindoles
  申请人：Hoffmann-La Roche Inc.

  公开号：US06252086B1

  公开（公告）日：2001-06-26

  Disclosed are novel 4-alkenyl- and 4-alkynyl oxindoles having the formula and the pharmaceutically acceptable salts thereof. These compounds inhibit cyclin-dependent kinases (CDKs), in particular CDK2. These compounds and their pharmaceutically acceptable salts, and prodrugs of said compounds, are anti-proliferative agents useful in the treatment or control of cell proliferative disorders, in particular cancer, more particularly, the treatment or control of breast and colon tumors. Also disclosed are pharmaceutical compositions containing the compounds of formula I and II as well as intermediates useful in the preparation of the compounds of formula I and II.

  本发明涉及具有以下公式和其药学上可接受的盐的新型4-烯基和4-炔基氧吲哚。这些化合物抑制细胞周期蛋白依赖性激酶（CDKs），特别是CDK2。这些化合物及其药学上可接受的盐和前药是抗增殖剂，可用于治疗或控制细胞增殖性疾病，特别是癌症，更特别是乳腺和结肠肿瘤的治疗或控制。本发明还涉及包含公式I和II的化合物的制药组合物，以及制备公式I和II的化合物的中间体。
• 4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
  申请人：Hoffmann-La Roche Inc.

  公开号：US06313310B1

  公开（公告）日：2001-11-06

  Disclosed are 4- and 5-alkynyloxindoles as well as 4- and 5-alkenyloxindoles that inhibit or modulate protein kinases, in particular JNK protein kinases. The compounds of the invention and their pharmaceutically acceptable salts, and prodrugs of said compounds, are useful as anti-inflammatory agents, particularly useful in the treatment of rheumatoid arthritis. Also disclosed are pharmaceutical compositions containing the foregoing compounds, methods for the treatment and/or control of inflammation, particularly in the treatment or control of rheumatoid arthritis using these compounds, as well as intermediates useful in the preparation of compounds of the invention.

  本发明涉及4-和5-炔基氧吲哚以及4-和5-烯基氧吲哚，这些化合物能够抑制或调节蛋白激酶，特别是JNK蛋白激酶。本发明的化合物及其药学上可接受的盐和前药，可用作抗炎剂，特别适用于治疗类风湿关节炎。本发明还涉及含有上述化合物的制药组合物，使用这些化合物治疗和/或控制炎症的方法，特别是使用这些化合物治疗或控制类风湿关节炎，以及在制备本发明化合物中有用的中间体。
• 4-Alkenyl- and 4-alkynyloxindoles
  申请人：Hoffmann-La Roche Inc.

  公开号：US06130239A1

  公开（公告）日：2000-10-10

  Disclosed are novel 4-alkenyl- and 4-alkynyl oxindoles having the formula ##STR1## and the pharmaceutically acceptable salts thereof, wherein R.sup.1, R.sup.2, R.sup.3, a, b, and X are as defined herein. These compounds inhibit cyclin-dependent kinases (CDKs), in particular CDK2. These compounds and their pharmaceutically acceptable salts, and prodrugs of said compounds, are anti-proliferative agents useful in the treatment or control of cell proliferative disorders, in particular cancer, more particularly, the treatment or control of breast and colon tumors. Also disclosed are pharmaceutical compositions containing the compounds of formula I and II as well as intermediates useful in the preparation of the compounds of formula I and II.

  本发明涉及一种新型的4-烯基和4-炔基吲哚，其化学式为##STR1##以及其药学上可接受的盐，其中R.sup.1，R.sup.2，R.sup.3，a，b和X的定义如本文所述。这些化合物抑制细胞周期依赖性激酶（CDKs），特别是CDK2。这些化合物及其药学上可接受的盐和前药是抗增殖剂，用于治疗或控制细胞增殖性疾病，特别是癌症，更特别是用于治疗或控制乳腺和结肠肿瘤。本发明还涉及包含化合物I和II的制药组合物，以及用于制备化合物I和II的中间体。
• Pyrrolo-nitrogenous heterocyclic derivatives, the preparation and the pharmaceutical use thereof
  申请人：Shanghai Hengrui Pharmaceutical Co., Ltd.

  公开号：US08329682B2

  公开（公告）日：2012-12-11

  The invention provides new pyrrolo-nitrogenous heterocyclic derivatives represented by formula (I) or their salts, the preparation thereof, pharmaceutical compositions containing such derivatives and the use of such derivatives as therapeutic agents, especially as protein kinase inhibitors, wherein each substituent in formula (I) is same as defined in the description.

  该发明提供了由式（I）表示的新的吡咯-含氮杂环衍生物或其盐，其制备方法，含有这种衍生物的药物组合物以及将这种衍生物用作治疗剂，特别是作为蛋白激酶抑制剂的用途，其中式（I）中的每个取代基与描述中定义的相同。
• Methods of Inhibiting the Catalytic Activity of a Protein Kinase and of Treating a Protein Kinase Related Disorder
  申请人：JIANGSU HANSOH PHARMACEUTICAL CO., LTD.

  公开号：US20130303518A1

  公开（公告）日：2013-11-14

  The invention provides a method of inhibiting the catalytic activity of a protein kinase comprising contacting said protein kinase with a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the same, and also provides a method of treating a protein kinase related disorder comprising a step of administering to a patient in need thereof a therapeutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the same, wherein each substituent in formula (I) is same as defined in the description.

  本发明提供了一种抑制蛋白激酶催化活性的方法，包括将该蛋白激酶与式(I)的化合物或其药学上可接受的盐或含有该化合物的制剂接触。本发明还提供了一种治疗与蛋白激酶相关的疾病的方法，包括向需要治疗的患者施用式(I)的化合物或其药学上可接受的盐或含有该化合物的制剂的治疗有效量。式(I)中的每个取代基与说明书中定义的相同。